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Abstract Patients suffering from familial hypercholester-
olemia (FH) are characterized by increased plasma levels of
low-density lipoprotein cholesterol (LDL-C) levels and are
at increased risk for premature cardiovascular disease
(CVD). Current guidelines emphasize the need to aggres-
sively lower LDL-C in FH patients, and statins are the
cornerstone in the current regimen. However, additional
therapies are eagerly awaited, especially for those patients
not tolerating statin therapy or not reaching the goals for
therapy. Our understanding of LDL metabolism has
improved over the last years and an increasing number of
potential novel targets for therapy have been recently
identified. Apart from novel targets, we have also been
confronted with novel modalities of treatment, such as
mRNA antisense therapy. Some of these emerging therapies
have proven to be effective in lowering plasma LDL-C
levels and are as such expected to have beneficial effects on
CVD. Hopefully, they will enrich our armamentarium
against the severe dyslipidemia observed in FH patients in
the not too distant future.
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Clinical Trial Acronyms
AIM-HIGH Atherothrombosis Intervention in
Metabolic Syndrome with Low HDL/
High Triglycerides and Impact on
Global Health Outcomes
ASAP Atorvastatin Versus Simvastatin on
Atherosclerosis Progression
HPS-2-Thrive Treatment of High-Density Lipoprotein
to Reduce the Incidence of Vascular
Events
HPS3/REVEAL Randomized Evaluation of the Effects of
Anacetrapib Through Lipid Modification
ILLUMINATE Investigation ofLipid LevelManagement
to Understand Its Impact in Atheroscle-
rotic Events
RADIANCE I Carotid B-Mode Ultrasound Study to
Compare Anti-Atherosclerotic Effect of
Torcetrapib/Atorvastatin to Atorvastatin
Alone
SHARP Study of Heart and Renal Protection.
Introduction
Familial hypercholesterolemia (FH) is an autosomal-dominant
disorder characterized by elevated plasma low-density lipo-
protein cholesterol (LDL-C) levels. Mutations in the gene
encoding for the LDL receptor are the underlying molecular
defect in the vast majority of FH patients [1], but mutations in
APOB [2]a n dPCSK9 have also been shown to result in
Mendelian forms of increased LDL-C levels [3]. FH patients
are at sharply increased lifetime risk for cardiovascular
disease (CVD) and, if left untreated, clinical symptoms of
CVD typically manifest in men in their fourth decade and in
women in their fifth decade of life [4]. Apart from the
elevated LDL-C levels, other traditional CVD risk factors (ie,
smoking, hypertension, diabetes) do add to the total risk in
FH patients, and all modifiable risk factors should therefore
be aggressively addressed. Current guidelines recommend
lowering the LDL-C concentration to at least 50% from
baseline. Statins are shown to safely lower LDL-C levels and
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DOI 10.1007/s11886-011-0219-9are therefore the treatment of choice [5, 6]. Moreover,
large clinical trials have provided us with overwhelming
evidence that statins reduce cardiovascular mortality and
morbidity [7••].
However, treatment goals are not achieved in a signif-
icant number of FH patients [8–10]. In such patients, and in
case statin therapy is contraindicated or poorly tolerated,
alternative lipid-lowering medications should be initiated.
Ezetimibe, bile acid sequestrants, nicotinic acid, and
fibrates are frequently prescribed as add-on therapy to
initial treatment with statins [6].
In recent years, several novel promising therapeutic
strategies for LDL-C lowering have been developed. In this
review, we discuss the present and future treatment options
for lipid lowering in FH patients, especially those medi-
cations that have been shown, or are anticipated, to result in
LDL-C reduction.
Currently Approved Lipid-Lowering Therapy
Lifestyle Modification
In FH patients, lifestyle modification to lower LDL-C and
reduce other CVD risk factors should be introduced, despite
the modest and variable degree of LDL-C reduction (10%).
A diet containing less than 7% saturated fat and less than
200 mg of cholesterol is to be advised. Additional use of
plant sterol esters or plant stanol esters will reduce LDL-C
levels, although trials showing a beneficial effect of these
substances on CVD outcome are lacking [11, 12]. Patients
should be encouraged to achieve and maintain a healthy
body weight through physical activity and appropriate
caloric intake. Alcohol consumption should be restricted
and smoking should be discouraged, as it is strongly
associated with CVD in patients with hypercholesterolemia
[13, 14]. It should be kept in mind that lifestyle modification
is rarely, if ever, sufficient to achieve the LDL-C treatment
goal in patients with FH and drug therapy is therefore
required in almost all patients.
Statins
Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors (Table 1). They inhibit the rate-
limiting step in cholesterol synthesis by reducing the
conversion of HMG-CoA reductase to mevalonate. The
consequently decreased intracellular cholesterol levels induce
an upregulation of the LDL receptor, which leads to
increased clearance of LDL-C and decreased plasma
LDL-C concentrations [15]. Apart from the reduction in
LDL-C, statins have been shown to improve endothelial
function, stabilize atherosclerotic plaques, decrease oxidative
stress and inflammation, and inhibit the thrombogenic
response [16].
Statins have convincingly been shown to be safe and
well-tolerated agents that reduce CVD morbidity and
mortality in a wide range of patients [17]. Therefore,
guidelines recommend these drugs as the first-line therapy
in patients with FH.
Statins are the most commonly prescribed drugs in FH
patients [18] and their impact on the natural cause of
vascular disease in FH is large. Observational data from
large FH cohorts suggest that long-term statin treatment
removes the excess lifetime risk of CVD due to FH and
reduced it to a level similar to that of the general population
[19, 20].
Statins reduce LDL-C levels in a dose-dependent manner
[7••], and the rationale to treat FH patients with high
dosages of these therapeutics is based on clinical trials
showing benefit in terms of reductions of cardiovascular
events and death [21]. Although trials with events as
primary outcome are lacking in FH patients, the ASAP trial
showed a beneficial effect of intensified therapy on carotid
intima-media thickness (cIMT), a surrogate marker of
atherosclerosis [22]. FH patients should initially be treated
with more potent statins, which have been shown to reduce
LDL-C levels by 50% to 60% at their maximum approved
doses [23]. Initial concerns about the safety profile of
statins, especially in children, have been refuted by a
number of clinical trials [24–26].
Other Currently Available Treatment Options
In many FH patients, LDL-C treatment goals cannot be
reached with the maximum available or tolerated dose of a
statin. In such cases, adding ezetimibe, a bile acid binding
resin, fibric acid derivates, or nicotinic acid should be
considered. In homozygous FH individuals or in heterozy-
gous FH patients at extreme risk (which is not uniformly
specified), LDL apheresis has been shown to be an
effective means to reduce LDL-C as well.
Ezetimibe selectively inhibits the intestinal absorption of
both dietary and biliary cholesterol by blocking the
Niemann-Pick C1-like 1 (NPC1L1) protein transporter,
which reduces the delivery of intestinal cholesterol to the
liver (Table 1). As a result, the LDL receptor expression is
upregulated and clearance of LDL-C from plasma is
increased. In patients with FH, ezetimibe can be safely
coadministrated with statins [27]. Ezetimibe reduces LDL-
C by approximately 15% to 20% [28, 29•]. The clinical
benefit of adding ezetimibe to statin therapy has not been
proven. In fact, in a large clinical trial in which adult FH
patients were randomized to statin or a combination of
statin and ezetimibe, no effect was found on the extent of
atherosclerosis assessed by cIMT, despite a significant
528 Curr Cardiol Rep (2011) 13:527–536reduction in LDL-C in the combination therapy arm [29•].
A possible explanation for this rather counterintuitive
finding is the fact that the baseline cIMT measured in the
enrolled patients was not as severely affected as anticipated.
The potential beneficial effect of ezetimibe is demonstrated in
a recent analysis, in which ezetimibe was shown in FH
patients to not only result in significant reductions in LDL-C
but also in other CVD-associated plasma markers in FH
patients [30]. The SHARP trial showed a beneficial effect on
CVD risk (risk reduction, 17%; P= 0 . 0 0 2 )o fs i m v a s t a t i n
Table 1 Currently approved therapeutics for lipid lowering
Agent Mechanism of action Effects on lipid profile Adverse effects
HMG-CoA
reductase
inhibitors (statins)
Inhibition of HMG-CoA reductase,
the rate-limiting enzyme in
cholesterol synthesis
LDL↓ up to ~50% Myopathy, rhabdomyolysis
(extremely rare),
hepatoxicity
Atorvastatin HDL ↑ up to~10%
Fluvastatin TG ↓ up to~20% [76]
Lovastatin
Pravastatin
Rosuvastatin
Simvastatin
Ezetimibe Inhibition of cholesterol absorption
by interfering Niemann-Pick
C1-like 1 protein, responsible for
transluminal cholesterol transport
LDL ↓~15% Gastrointestinal symptoms
HDL variable, but not
clinically relevant
[77, 78]
TG no significant
change [78]
Bile acid
sequestrants
Decrease of the hepatocyte
cholesterol content, resulting in
an upregulation of the LDLR
expression and increased LDL
cholesterol clearance
LDL ↓ 18%
a Gastrointestinal symptoms
including constipation and
dyspepsia
Colesevelam HDL no significant
change
Colestipol TG variable [79, 80]
Cholestyramine
Nicotinic acids Unclear LDL ↓ 12% Flushing
Niacin HDL ↑ 16% Gastrointestinal symptoms
TG ↓ 20% [81] Hepatotoxicity
Hyperglycemia
Fibrates Probably mediated by agonizing
PPAR-α
LDL ↓ 8% Rhabdomyolysis
Bezafibrate HDL ↑ 9% to 10% Liver failure
b
Ciprofibrate TG ↓ 30% to 36%
[81, 82]
especially in combination
with statins (extremely
rare)
Gemfibrozil
Fenofibrate
↑ = Increase; ↓ = Decrease
aData from pooled analysis of statin-colesevelam trials showed LDL lowering of 9%. Depending on statin use, LDL lowering up to 18% was
shown
bOther side effects mentioned in the meta-analysis from Birjmohun et al. [81] included skin reactions, musculoskeletal symptoms, and
hepatotoxicity. However, the occurrence of these side effects did not significantly differ from the side effects reported in the control groups
HDL high-density lipoprotein; HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme A; LDL low-density lipoprotein; LDLR low-density lipoprotein
receptor; PPAR-α peroxisome proliferator-activated receptor-α; TG triglycerides
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cohort (> 9000) patients suffering from chronic kidney
disease. In this study, the combination therapy was not
associated with altered risk of myopathy or cancer during the
4.9 years of follow-up [31]. Although there is no direct
clinical evidence that ezetimibe would result in a beneficial
vascular outcome, it is reasonable to consider it as add-on
therapy to statins in FH patients given its tolerability and
safety.
Bile acid binding resins act by binding to bile acids in the
intestinal lumen. This interrupts the enterohepatic circulation
of bile acids, leading to increased conversion of cholesterol
intobileinthe liver.The resultingdecreasedcholesterollevels
in the hepatocytes induce a hepatic upregulation of LDL
receptor activity, causing an increased clearance of LDL-C
from the circulation by up to 20% [32]. Because bile acid
binding sequestrants act in the intestinal lumen and are not
systemically absorbed, they are considered to be safer than
other lipid-lowering drugs. However, cholestyramine and
colestipol are associated with significant adverse gastroin-
testinal side effects, drug-drug interactions, and poor patient
compliance. The second-generation bile acid sequestrant
colesevelam can be used at a lower dose and is associated
with less gastrointestinal side effects, and is therefore
currently the recommended bile acid sequestrant for use in
patients with FH in combination with statins [33].
The mechanism of action of fibric acid derivates is
complex and largely unknown, but is commonly thought to
be mediated via a peroxisome proliferator-activated
receptor-α regulated mechanism. Treatment with fibrates
results in decreased production of very low density
lipoprotein cholesterol (VLDL-C) and an increased clear-
ance of triglycerides. Fibrates have also shown to lower
total cholesterol and LDL-C and elevate HDL-C to some
extent (Table 1). Adverse reactions are to some extent
similar to statins (Table 1); however, the combination of
fibrates, most notably gemfibrozil, with statins will increase
the risk of myopathy or rhabdomyolysis [34], and therefore
fibrates are not recommended in FH patients without
elevated triglyceride levels.
The mechanism of action of nicotinic acid or niacin is
not fully understood. Niacin is a water-soluble B vitamin
and favorably affects VLDL, LDL-C, and increases HDL-
C. The adverse effects of niacin (Table 1), mainly flushing
due to vasodilatation, are considered a major drawback, but
by combining niacin with a prostaglandin D2 inhibitor
(laropiprant), this side effect was significantly decreased
[35–37]. A meta-analysis has shown cardiovascular risk
benefit of niacin in terms of reduction of cardiovascular
events and atherosclerosis [38], but a more definitive
answer regarding CVD reduction of niacin will be provided
by the HPS-2-Thrive study. As for all other agents,
however, no conclusions can be drawn regarding the benefit
of niacin added to statin therapy in FH patients. The AIM-
HIGH trial investigated whether adding extended-release
niacin to statin treatment in high-risk patients would be
beneficial in risk reduction. This trial has recently been
stopped prematurely by the National Heart, Lung, and
Blood Institute after 18 months, because no effect was
shown in the interim analysis (http://public.nhlbi.nih.gov/
newsroom/home/GetPressRelease.aspx?id=2792).
LDL apheresis may be considered for homozygous FH
patients or heterozygous FH patients who require intensi-
fication of therapy because of high LDL-C levels despite
a maximal dose of statins and/or multiple other risk
factors for CVD. LDL apheresis selectively removes apo
B–containing lipoprotein particles from the circulation with
extracorporeal precipitation through different techniques,
resulting in an LDL-C reduction of approximately 60%
[39]. Furthermore, it reduces lipoprotein (a) levels by more
than 50%. The procedure is time consuming, must be
repeated every 1 to 2 weeks, and is costly. However, several
clinical trials have shown that LDL apheresis delays the
progression of CVD [40].
Future Lipid-Lowering Therapy
Antisense Oligonucleotides to Inhibit Apolipoprotein B
Production
Apolipoprotein B (apo B) is mainly expressed in the liver
and is regarded as an essential protein at core and on the
surface of atherogenic lipoproteins. It is crucial for the
production of VLDL (the precursor of LDL) and following
secretion by the liver, apo B is bound to its lipoprotein
particle. Apo B is also pivotal for the subsequent clearance
of cholesterol transported by lipoproteins; upon binding to
the LDL receptor, cholesterol is withdrawn from the plasma
pool [41]. In FH patients apo B levels are invariably
increased, and large prospective studies have shown that
apo B levels are directly associated with CVD risk [42]. In
line with this, patients with extremely low levels of apo B
(< 5th percentile) due to familial hypobetalipoproteinemia
seem to be protected against CVD [43, 44] .B a s e do nt h e s e
observations apo B is conceptually an attractive target
to reduce CVD risk. Mipomersen (formerly known as
ISIS-301012), a second-generation apo B synthesis
inhibitor, is the first agent available for human use to
directly target apo B100 production. This subcutaneous-
ly administered short single-stranded synthetic oligonu-
cleotide is complementary to apo B100 mRNA, and
upon binding to the mRNA, degradation by endogenous
RNase-H takes place. This subsequently results in
inhibition of synthesis of the apo B protein, and a
decrease in VLDL and LDL levels [45].
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effect on apo B and LDL as well as on all other atherogenic
particles. The highly significant dose reductions in LDL-C
(Table 2) were confirmed in a number of studies, including
trials in FH patients [47–50]. The effect on plasma lipids
was shown not to be influenced by coadministration of
other lipid-lowering medication [47, 50]. In addition to its
beneficial effect on LDL-C, mipomersen also lowered
serum levels of apo B, triglycerides, and lipoprotein (a).
A dose of 200 mg of mipomersen once weekly adminis-
tered subcutaneously was selected for further evaluation in
phase 3 clinical trials. Reductions in LDL-C lasted up to
4 weeks after the last dose and pharmacokinetic studies
showed no clinically relevant interactions of mipomersen
with the disposition and clearance of simvastatin or
ezetimibe [51], which is pivotal for the role of mipomersen
as additive medication.
In a recently published double-blind trial, 51 homozy-
gous FH patients, treated with maximum tolerated dosages
of lipid-lowering medications, were randomly assigned to
mipomersen, 200 mg, subcutaneously every week or
placebo. After 26 weeks of treatment, a mean reduction in
LDL-C of 25% was observed in the mipomersen-treated
group versus 3% in placebo-treated patients (P<0.001). In
addition, patients treated with mipomersen experienced a
27% reduction in apo B and a 21% reduction in total
cholesterol. No correlation was found between the LDL
receptor mutation and response to therapy [50].
Similar reductions in LDL-C levels (28%) were shown
in a study conducted in 124 patients with heterozygous FH,
who were on maximally tolerated statin therapy and had a
history of coronary heart disease. It is of note that 45% of
these high-risk patients treated with mipomersen reached
the treatment goal of LDL-C below 100 mg/dL [52].
Mipomersen is well tolerated and commonly described
adverse events include injection site reactions, flu-like
symptoms, and increases in alanine aminotransferase. The
latter were shown not to be directly related to increased
steatosis, as being measured in a study using magnetic
resonance spectroscopy [53].
Mipomersen should be considered a potential novel
treatment modality in FH, given its lipid-lowering effect,
relatively easy mode of administration, and lack of interac-
tions with other lipid-modifying drugs.
PCSK9 Targeted Therapy
After the initial report that gain-of-function mutations in the
gene encoding for proprotein convertase subtilisin/kexin type
9 (PCSK9) cause Mendelian hypercholesterolemia [3],
PCSK9 has gained large interest as a target for lipid
lowering. PCSK9 has been shown to be a pivotal regulator
of LDL-C metabolism by virtue of its role in lysosomal
degradation of the LDL receptor within hepatocytes. The
notion that loss-of-function PCSK9 mutations confer an 80%
CVD risk reduction [54] has further substantiated the role of
PCSK9 as a potential target. Although PCSK9 could be
anticipated to act as a protease on other substrates as well, it
is of importance to note that subjects with lifelong half
normal activity of PCSK9 due to loss-of-function mutations
were not characterized by other untoward clinical features.
A number of strategies to specifically lower PCSK9
activity are currently in different stages of development and
testing: antisense nucleotide-based therapy (similar to
mipomersen described above) [55], monoclonal antibodies
binding to the catalytic site of PCSK9 (eg, AMG 145,
1D05-IgG2, and REGN727), and small interfering RNAs.
Although animal studies have shown beneficial effects
of use of these novel compounds (with LDL lowering up to
80%) [56, 57], no human studies on the effect of either of
these different strategies have been published thus far. The
finding, however, that statins and fibrates induce increased
PCSK9 expression [58] further underlines that PCSK9
inhibition could induce robust LDL-C reductions as add-on
therapy and a number of phase 2 and phase 3 trials will
likely be initiated soon.
Microsomal Triglyceride Transfer Protein Inhibitors
Microsomal triglyceride transfer protein (MTP) plays an
important role in the hepatic assembly of plasma lip-
oproteins, by mediating the transfer of triglycerides to
VLDL [59, 60]. MTP mutation carriers are characterized
by hypobetalipoproteinemia [61] and one could therefore
anticipate an MTP-lowering therapy to result in a decrease
of VLDL and LDL-C levels (Table 2). Cuchel et al. [62]
showed that MTP inhibition by means of BMS-201038 gave
rise to approximately 50% reductions of plasma LDL-C levels
in the highest dosage (0.1 mg/kg/day). However, this trial,
performed in six homozygous FH patients [62], also showed
that MTP inhibition induced an increase in hepatic steatosis.
This finding raised serious concerns, and the drug is therefore
only studied at its higher dosages in homozygous FH patients
where LDL-C reduction is considered to outweigh potential
steatosis. The maximum studied dose in a subsequent trial in
10 homozygous patients was 60 mg/day, and this regimen
resulted in a 44% reduction in LDL-C levels, over and above
the effect already achieved by coadministered other lipid-
modifying medication [63]. The extent of steatosis in this trial
was reduced compared with the initial trial.
A low-dose regimen of MTP inhibition was studied by
Samaha et al. [64]. The 84 patients with hypercholesterolemia
were randomized to ezetimibe, 10 mg, daily (n=29); MTP
inhibition by lomitapide (also known as AEGR-733 and
BMS −201038) in increasing dosages (5.0, 7.5, and 10 mg
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Agent Phase of
investigation
Mechanism of action Effect on lipid profile Adverse effects
Apolipoprotein B
synthesis inhibitors
Mipomersen
Phase 2 and 3 Inhibition of apolipoprotein B
production
LDL ↓ 21% to 52% (dose
dependent)
Injection side reactions
HDL variable (range: no
significant change to
↑ 15.1%)
Increase of alanine
aminotransferase levels
TG: variable (range: no
significant change to ↓ 17%
to 41% [47, 48, 50]
a
Thyroid mimetics:
Eprotirome
Phase 2 Selective affinity for thyroid
receptor β, which is expressed
in the liver. Induction of
metabolic beneficial pathways
LDL ↓ 22% to 32% Abdominal pain and
gastrointestinal side effects;
mild increase of
transaminase levels
HDL ↓ 5% to 6%
TG ↓ 16% to 33% [65, 83]
b
PCSK9 inhibitors Phase 1 Inhibition of PCSK9; protease
which inhibits the expression of
LDL receptors
PCSK9 inhibitors are
currently being investigated
in phase 1 clinical trials
PCSK9 inhibitors are
currently being investigated
in phase 1 clinical trials
MTP inhibitors Phase 2 and 3 Inhibition of MTP, thereby
interfering in the assembly of
plasma lipoproteins in the liver
by mediating the transfer of
triglycerides and onto VLDL
(liver) and chylomicron
(intestine)
LDL ↓ 25% to 51% Gastrointestinal side effects
HDL variable (range: no
significant change to
↓ 10.4%)
Increase of transaminase
levels and hepatic fat
accumulation
TG ↓ 34% to 65% [62]
CETP inhibitors Phase 3 Inhibition of CETP, which
mediates the exchange of
cholesteryl esters from HDL to
LDL particles
Torcetrapib [84]
c Increase of transaminase
levels
Torcetrapib LDL ↓ 8% to 29% Flu like symptoms
HDL ↑45% to 72% The ILLUMINATE trial was
terminated early because of
increased mortality and
morbidity in patients
treated with torcetrapib on
top of a statin [72]
Dalcetrapib TG ↓18% to ↑ 14%
Dalcetrapib [84]
d
LDL ↓ 6%
HDL ↑ 27% to 28%
TG ↓ 0% to 8%
Anacetrapib Anacetrapib [74, 84]
e
LDL ↓ 27% to 62%
HDL ↑ 80% to 139%
TG ↓ 30% to ↑ 18%
↑ = Increase, ↓ = Decrease
aChanges mentioned are in subjects on conventional lipid-lowering therapy at baseline
bEffects shown are in addition to statin therapy after 12 weeks of treatment with eprotirome dosages ranging from 25 to 100 μg
cData shown include treatment in subjects with HDL less than 40 mg/dL, healthy subjects, subjects with mixed dyslipidemia, heterozygous FH
patients, patients with type IIB hyperlipidemia, high-risk patients, patients with CAD, patients with HDL levels below average, and patients with
HDL levels below average and eligible for statin treatment
dData shown include treatment in subjects with HDL less than 60 mg/dL and subjects with type II dyslipidemia
eData shown include treatment in subjects with LDL 100 to 190 mg/dL or 100 to 160 mg/dL and moderate risk of CAD, treatment in subjects
with primary hypercholesterolemia or mixed hyperlipidemia, and treatment in healthy subjects
CAD coronary artery disease; CETP cholesterol ester transfer protein; FH familial hypercholesterolemia; HDL high-density lipoprotein;
ILLUMINATE Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events; LDL low-density lipoprotein; MTP
microsomal triglyceride transfer protein; PCSK9 proprotein convertase subtilisin/kexin type 9; TG triglycerides; VLDL very low density
lipoprotein
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10 mg daily, and lomitapide administered with the dose
titration described above (n=28). Ezetimibe therapy resulted
in an expected LDL-C reduction of 20%. Lomitapide was
shown to induce a lowering of LDL-C levels in a dose-
dependent manner: 19%, 26%, and 30% in the 5-, 7.5-, and
10-mg dosing regimens, respectively. Combined therapy
produced similar but larger dose-dependent decreases (35%,
38% and 46%, respectively). Mild transaminase elevations
(n=9) and diarrhea were the primary cause for discontinua-
tions from lomitapide (Table 2). Despite the fact that MTP
inhibition induced steatosis in high dosages, one might
consider MTP an attractive candidate for lipid lowering in
FH patients if administered in lower dosages.
Thyroid Mimetics
The notion that hyperthyroidism results in sharply de-
creased LDL-C levels reduced has driven the attempts to
mimic this by administration of thyroid hormone analogues.
As seen in hyperthyroidism, however, these therapies (D-
thyroxine and tiratricol) failed, due to the associated cardiac
and bone-related side effects.
Recently, the differential molecular mechanisms underlying
the“beneficial”(mainlyviathethyroidreceptor-β[TRβ]route;
this receptor is mainly exp r e s s e di nt h el i v e r )a n d“deleterious”
aspects (mediated by TRα [expressed in brain and heart]–
induced processes) of hyperthyroidism have been elucidated.
Eprotirome (KB2115; Karo Bio AB, Stockholm, Sweden),
sobetirome (QRX-431/GC-1; formerly owned by QuatRx
Pharmaceuticals, Ann Arbor, MI), and MB07811 (Ligand
Pharmaceuticals, La Jolla, CA) are selective TRβ agonists and
they are currently in different stages of investigation.
A recent study showed the effects of adding eprotirome
to standard statin therapy [65]. In this 12-week trial,
Ladenson et al. [65] enrolled 184 patients, who were treated
with placebo or eprotirome on top of a statin (simvastatin≤
40 mg and atorvastatin≤20 mg daily). Randomization to
placebo or eprotirome in three dosages (25, 50 and 100 ug
daily) resulted in a decrease of LDL-C level by 7%, 22%,
28%, and 32%, respectively (Table 2). Eprotirome was not
associated with adverse events on heart (arrhythmia) or bone
(serum markers of bone turnover) [65]. A large phase 3 trial
will start in FH patients in the near future.
Sobetirome and MB07811 have not been tested for their
effect on dyslipidemia in humans, but the beneficial effect
of eprotirome on LDL-C levels in non-FH patients holds
promise for FH patients.
Cholesterol Ester Transfer Protein Inhibitors
The HDL-bound enzyme cholesterol ester transfer pro-
t e i n( C E T P )m e d i a t e st h ep r o c e s so ft r a n s f e ro fc h o l e s -
teryl esters from HDL particles to apolipoprotein B–
containing particles [66]. Elevated CETP levels were
shown to be associated with an increased risk for coronary
artery disease in apparently healthy subjects [67], and
inhibition of CETP in rabbit models of atherosclerosis
dramatically reduced the extent of the disease [68]. Two
approaches to inhibit CETP activity have been described;
a vaccine-based strategy and a small molecule inhibitor-
mediated method.
CETi-1 (Avant Immunotherapeutics, Needham, MA) is a
synthetic peptide that includes residues of the human CETP
protein. Upon administration, this vaccine raises an immune
response and production of autoantibodies against CETP.
Initial animal studies showed the efficacy of this vaccine to
increase HDL-C levels and reduce aortic atherosclerosis
[69]. However, the phase 1 trial in humans showed a
relatively poor response in terms of the presence of
autoantibodies (in 1 out of 23 patients) and the effect on
plasma lipid levels was negligible [70].
Torcetrapib (Pfizer, New York, NY), anacetrapib
(MK-0895; Merck, White House Station, NJ), dalcetrapib
(formerlyknownasJTT-705; Roche, Basel,Switzerland),and
evacetrapib (LY2484595; Eli Lilly; Indianapolis, IN) are
molecules that antagonize CETP activity by binding to the
protein. The reason why these primarily HDL-C–increasing
medications are mentioned in this review is the fact that
torcetrapibistestedinFHpatientsandthatallCETPinhibitors
have been shown to beneficially affect LDL-C levels.
The RADIANCE I trial, in which over 800 patients
with FH were enrolled, showed that addition of
torcetrapib to atorvastatin did not result in reduction
of atherosclerosis, as assessed by intima-media thick-
ness [71], despite a significant reduction in LDL-C (21%)
and increase in HDL-C (52%). These findings are in line
with the ILLUMINATE trial, which was prematurely
terminated because of unexpected increased mortality
and morbidity in patients treated with atorvastatin com-
bined with torcetrapib [72]. The exact mechanism under-
lying this counterintuitive finding is not fully elucidated,
but a recent chemical systems biology analysis shed light
on this topic. The study suggested the presence of off-
target effects of torcetrapib, and these might partially
explained by the blood pressure increase induced by
torcetrapib [73]. The fact that the other CETP inhibitors
do not show an effect on blood pressure further confirms a
molecule-specific off-target effect.
The two remaining CETP inhibitors in phase 3 develop-
ment, anacetrapib and dalcetrapib, have been shown to be
effective lipid modifiers [74, 75], but the cardiovascular
outcome trials (DAL-outcomes I and II and HPS3/REVEAL)
are eagerly awaited. Once shown to benefit mild hypercho-
lesterolemic patients and other patients at CVD risk, CETP
inhibition is likely to benefit patients with FH.
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During the last decade we have been confronted with an
increase in our understanding of human lipid biology. This
knowledge has given great impetus to the identification of
novel strategies to inhibit specific pathways in dyslipidemia.
UponapprovalofefficacyinCVDreduction,theseagentswill
be beneficial for all patients at risk, such as FH patients.
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